Androgen replacement therapy

Annals of Medicine

Volumn 29, Issue 5, 1997, Pages 365-370

  Wang, Christina ^a   Swerdloff, Ronald S ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Ageing men; Pharmacokinetics; Risks and benefits; Testosterone

Indexed keywords

ANDROGEN; TESTOSTERONE;

ANDROGEN THERAPY; CONTRACEPTION; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; MALE; MUSCLE ATROPHY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SUBLINGUAL DRUG ADMINISTRATION; TESTOSTERONE BLOOD LEVEL; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0030694318     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899708999363     Document Type: Review

References (14)

1. Nieschlag E, Behre HM, eds. Testosterone: Action, Deficiency and Substitution. Berlin: Springer Verlag, 1990.
2. Bhasin S, Gabelnick H, Spieler J, Swerdloff RS, Wang C. Pharmacology, Biology and Clinical Applications of Androgens. New York: Wiley-Liss, 1996.
3. Wilson JD. Androgen abuse by athletes. Endocr Rev 1988; 9: 181-99.
4. Bagatell CJ, Bremner WJ. Androgens in men: uses and abuses. N Engl J Med 1996; 334: 707-14.
5. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092-8.
6. Sin R, Morley JE, Kaiser FE, Perry HM III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661-7.
7. Haseltine F, Paulsen CA, Wang C, eds. Reproductive Issues and the Aging Male. Washington: American Association for the Advancement of Science, 1993.
8. Bhasin S, Storer TW, Berman N, et al. Effects of supraphysiologic doses of testosterone on muscle size and strength in healthy men. N Engl J Med 1996; 335: 1-7.
9. Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 407-13.
10. Dobs AS, Dempsey MA, Landeson PW, Polk BG. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1988; 84: 611-5.
11. Bhasin S, Swerdloff RS, Steiner B, et al. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. J Clin Endocrinol Metab 1992; 74: 75-83.
12. Behre HM, Nieschlag E. Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J Clin Endocrinol Metab 1992; 75: 1204-10.
13. Gooren LJG. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994; 15: 212-5.
14. Salehian B, Wang C, Alexander G, et al. Pharmacokinetics, bioefficacy and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate - a clinical research center study. J Clin Endocrinol Metab 1995; 80: 3567-75.